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ocrit (53 v 41), magnesium (2.1 v 2.0), platelet count (209,000 v 209,000), potassium (4.4
v 4.7), calcium (9.4 v 9.4), SBP during infusion (118 v 128). Change in FMD from base-
line to 15th infusion was not significantly different between groups (∆ FMD % chelation:
mean = 2.39; ∆ FMD % placebo: mean = -.53, p=.453).
Conclusions: PACT provides reassuring randomized data concerning a large number of
safety parameters monitored over a 15-week course of chelation therapy with EDTA. The
most reliable data concerning the safety and efficacy of chelation therapy for patients
with CHD will emerge from the NIH-funded Trial to Assess Chelation Therapy (TACT),
which will randomize 2,372 patients in a 2x2 factorial trial of EDTA and/or high-dose vita-
mins.
1023-90 Effects of Nitroglycerin on Erythrocyte Rheology and 
Oxygen Unloading: Microvascular Mechanisms in 
Relieving Myocardial Ischemia
Jian-Ping Bin, Howard Leong-Poi, Nicholas G. Fisher, D. Elizabeth Le, Jonathan 
Christiansen, Sanjiv Kaul, University of Virginia, Charlottesville, VA
Purpose: We hypothesized that myocardial blood flow (MBF) is enhanced to ischemic
tissue by the direct effect of nitroglycerin (NTG) on erythrocyte rheology and that anti-
ischemic effects of NTG are also afforded by its direct effects on O2 unloading .
Background: Investigations of the anti-ischemic properties of NTG, have been generally
focused on its systemic and coronary hemodynamic effects. At the microcirculatory level,
however, erythrocyte rheology and O2 unloading play an important role in determining
MBF and O2 delivery, respectively.
Methods and Results: Twelve dogs were studied at rest and during direct intracoronary
infusion of NTG (0.3-0.6µg·kg-1·min-1). All dogs had a resting flow-reducing single-vessel
stenosis. Half the dogs also had total occlusion of the remote coronary artery to remove
any collateral effects. Hemodynamics, MBF, WBη, erythrocyte charge (EC) and electroki-
netic mobility (EM), regional myocardial O2 delivery and consumption as well as tissue
O2 pressure (PO2) were determined. As compared to baseline, no changes in hemody-
namics were seen during intracoronary NTG. MBF increased significantly in the central
25% of the myocardium supplied by stenosis, which was associated with an approxi-
mately 19% decrease in WBη. There was a good correlation (r=0.87) between the two.
The decrease in WBη was caused by a decrease in EC and an increase in EM (r=0.83).
As compared to baseline, the % increase in tissue PO2 was significantly greater during
NTG than the % increase in MBF, indicating enhanced O2 unloading.
Conclusions: NTG directly affects microcirculatory erythrocyte rheology that is associ-
ated with an increase in MBF in the center of the ischemic bed. It also directly enhances
O2 unloading to the ischemic myocardium. Thus, direct microvascular affects of NTG
also contribute to its anti- ischemic properties.
1023-91 Relationship Between β-Adrenergic System 
Polymorphisms and Coronary Peak Flow Velocity Ratio 
in Women: Analysis From the National Heart, Lung, and 
Blood Institute-Sponsored Women's Ischemia 
Syndrome Evaluation (WISE)
Issam Zineh, Susan P. McGorray, Lacy L. Jernigan, Dennis M. McNamara, Daniel F. 
Pauly, C. Noel Bairey Merz, Carl J. Pepine, Julie A. Johnson, University of Florida, 
Gainesville, FL
Background: Coronary microvascular dysfunction is frequent in women presenting with
ischemic symptoms, but the pathophysiological basis is unclear. Genetic polymorphisms
in the adrenergic system were evaluated to gain insight into possible pathophysiological
mechanisms.
Methods: We studied WISE participants who underwent coronary angiography for evalu-
ation of ischemic symptoms. Angiography with Doppler ultrasonography was used to
measure average peak velocity ratio (APV-R) response to adenosine (Ad), acetylcholine
(Ach), and nitroglycerin (NTG). Patients were genotyped for polymorphisms of the β1-
adrenergic receptor (AR) (codons 49 and 389), β2AR (codons 16 and 27), and Gsα
(codon 131) using single-primer extension or luciferase-based assays. ANOVA and t-
tests were performed to compare the reactivity parameters by genotype. Data are pre-
sented as means ± SD. Due to significant differences in variant alleles by race, p-values
were adjusted for genotype-by-race interaction.
Results: Polymorphisms in the β1AR, β2AR, and Gsα were associated with differences in
APV-R response to NTG. Ser49 homozygotes (n=69) had diminished response com-
pared with Gly49 carriers (n=34), with APV-R of 2.14 ± 0.58 and 2.47 ± 0.62, respectively
(p=0.039). APV-R at codon 16 for Arg16Arg (n=26), Arg16Gly (n=48), and Gly16Gly
(n=29) were 2.27 ± 0.58, 2.33 ± 0.65, and 2.11 ± 0.59 (p=0.029). APV-R at codon 27 for
Gln27Gln (n=45), Gln27Glu (n=50), and Glu27Glu (n=9) were 2.28 ± 0.63, 2.32 ± 0.61,
and 1.82 ± 0.36, respectively (p=0.039). Finally, at Gsα codon 131, APV-R for +/+ (n=23),
+/- (n=51), and -/- (n=29) were 2.52 ± 0.62, 2.19 ± 0.65, and 2.19 ± 0.53 (p=0.036). β1AR
codon 389 (Arg◊Gly) was not associated with APV-R response to NTG in this population
(p=0.18). There were no associations between any genotypes and reactivity response to
Ad or Ach.
Conclusion: Polymorphisms in βARs and their G protein are associated with differences
in APV-R response to NTG in women undergoing angiography for evaluation of ischemic
symptoms. These data indicate a potential role of the adrenergic system in microvascular
dysfunction.
1023-92 Potential Beneficial Effects of Transdermal Capsaicine 
Patches on the Ischemic Threshold in Patients With 
Stable Coronary Disease
Gabriele Fragasso, Altin Palloshi, Maria Luisa De Benedictis, PierMarco Piatti, Lucilla 
Monti, Emanuela Setola, Alberto Cappelletti, Alberto Margonato, Istituto Scientifico/
Universita' San Raffaele, Milano, Italy
Background. Capsaicin has been shown to exert direct vasodilating effects through
increased calcitonine gene-related peptide (CGRP) release. However no data exist on its
effect following systemic administration.
Methods. Twelve male patients with stable coronary disease were selected for study. All
patients had a persistently positive exercise test despite full antianginal therapy. Accord-
ing to a double blind, placebo-controlled study, patients were randomised to placebo or
3g oleic capsaicin-containing patches, in 2 different days and with a 2-day interval
between treatments. Patients performed treadmill exercise testing according to the Bruce
protocol. Heart rate, systolic/diastolic blood pressure and rate-pressure product were
measured at rest, at the appearance of 1mm ST segment depression and at peak exer-
cise. Time to 1mm ST segment depression and to peak exercise, maximal ST segment
depression, cumulative maximal ST segment depression and the number of ECG leads
showing diagnostic changes were also measured. Blood samples for nitric oxide (NO)
and CGRP were drawn at baseline, at peak exercise, 2, 6 and 24 hours after exercise.
Results. On placebo, all patients had a positive ECG during exercise test. Only one
patient experienced angina, in both treatments. With capsaicin, 1 patient had a negative
exercise, while the remaining 11 increased time to 1mm ST depression (from 372±170 to
424±182 sec, p<0.03) and time to peak exercise (from 489±189 to 508±202 sec, p=0.29)
and decreased the total number of involved ECG leads (from 3.75±1.76 to 3.25±2.00
leads, p=0.05). CGRP levels were not significantly different between placebo and capsa-
icin treatment. Conversely, when on capsaicin, NO significantly increased at 6 hours. No
significant side effects were recorded. Conclusions. Transdermal capsaicin may
improve ischemic threshold in patients with stable coronary disease, probably through
NO-mediated arteriolar vasodilation
1023-93 Anti-Inflammatory Effects of the V-Protectant AGI-1067 
in the Canadian Antioxidant Restenosis Trial (CART-1)
Jean-Claude Tardif, Philippe L. L'Allier, Leonard Schwartz, Lawrence Title, Louise 
Laramee, Francois Reeves, Joel Lavoie, Marie-Claude Guertin, Jean Gregoire, Montreal 
Heart Institute, Montreal, PQ, Canada
AGI-1067, the mono-succinic acid ester of probucol, is a lipophilic vascular protectant
that reduces the expression of VCAM-1 and MCP-1 and has strong antioxidant proper-
ties equipotent to probucol. We have shown in CART-1 that AGI-1067 has favorable
effects on restenosis and the atherosclerotic non-PCI (reference) segments (Circulation
2003;107:552-8). The objective of the present study was to determine the effects of AGI-
1067 on markers of inflammation. Prior to PCI, 305 pts were randomly assigned to 1 of 5
treatment groups: placebo (n=61); probucol 500 mg BID (n=60); AGI-1067 70 mg (n=59),
140 mg (n=64), or 280 mg (n=61) QD. Pts were treated for 2 wks prior to and for 4 wks
after PCI. Fibrinogen plasma levels and circulating white blood cell (WBC) counts were
measured at baseline and at the end of the 6-wk dosing period. Results: Plasma levels of
fibrinogen at baseline were 3.73+/-1.29 in the placebo group, 3.70+/-0.98 in the probucol
group, and 3.63+/-1.13, 3.78+/-0.81 and 3.70+/-0.83 gm/L in the AGI-1067 70, 140 and
280 mg groups respectively (p=NS). After 6 wks of treatment, fibrinogen levels were
3.56+/-0.76 in the placebo group, 3.63+/-1.05 in the probucol group, and 3.37+/-1.17,
3.17+/-0.65 and 3.21+/-1.01 gm/L in the AGI-1067 70, 140 and 280 mg groups respec-
tively (p=0.03 for AGI-1067 140 mg vs placebo; p=0.07 for AGI-1067 280 mg vs placebo;
p=0.005 for AGI-1067 140 mg vs probucol; p=0.017 for AGI-1067 280 mg vs probucol).
WBC counts decreased from baseline to end of treatment by 0.51+/-1.31 in the placebo
group, 0.79+/-1.48 in the probucol group, and 0.59+/-2.06, 0.88+/-1.40 and 1.09+/-1.26 in
the AGI-1067 70, 140 and 280 mg groups respectively (p=0.025 for AGI-1067 280 mg vs
placebo; p=NS for probucol vs placebo). Fibrinogen levels after 6 wks of treatment corre-
lated inversely (p=0.07) with the previously described favorable effect induced by AGI-
1067 in atherosclerotic reference segments as assessed by intravascular ultrasound.
Conclusion: The vascular protectant/antioxidant AGI-1067 has anti-inflammatory effects
in patients with atherosclerosis. The CART-2 and ARISE (Aggressive Reduction of
Inflammation Stops Events) trials are testing the anti-inflammatory hypothesis with AGI-
1067.
1023-94 Comparative Effect of Trimetazidine Plus Sildenafil 
Versus Nitrates in the Control of Myocardial Ischemia 
During Sexual Activity
Giuseppe M. Rosano, Roberto Patrizi, Giuseppe Marazzi, Elena Cerquetani, Massimo 
Fini, Giuseppe Mercuro, San Raffaele Roma, Roma, Italy, University of Cagliari, Cagliari, 
Italy
A large proportion of patients with erectile dysfunction (ED) have coronary artery disease
(CAD). In these patients nitrate therapy that is a contraindication to the use of Sildenafil.
In order to assess whether trimetazidine is effective in controlling episodes of myocardial
ischemia during sexual activity in patients with (CAD) receiving chronic nitrates we stud-
ied 38 male patients (57+6 years) with proven CAD. Patients underwent 24 hour ECG
monitoring (AEM) at baseline, after one week of oral nitrate therapy (20 mg tds) and after
one week of Trimetazidine (20 mg tds). Patients were asked to have at least one sexual
intercourse during each AEM. Patients were instructed to take Sildenafil (100 mg) one
hour before the sexual intercourse performed at baseline and during therapy with Tri-
metazidine and Sildenafil Placebo (in blind) during therapy with nitrates. An improvement
in total ischemic burden was observed with both nitrates and Trimetazidine compared to
baseline (-3+2 vs –5+3 episodes/24 hours, p=0.07; -6+5 vs –8+3 minutes/24 hours,
p=0.07). Trimetazidine plus Sildenafil were more effective in controlling episodes of myo-
